Intravitreal injection of bevacizumab (Avastin, Genentech) at the time of phacoemulsification in diabetic patients without maculopathy protected against the development of postoperative macular edema, according to the findings of a prospective, randomized comparative study reported by Ashraf El Habbak MD, PhD.
“There is an increased risk of cataract in patients with diabetes, and in fact, 20% of all patients who undergo cataract surgery have diabetes,” said Dr. El Habbak, professor of ophthalmology, Benha University, Banha, Egypt. “Macular edema after cataract surgery can adversely affect visual outcome, and Kim et al. reported that 22% of diabetic patients had a >30% increase in central retinal thickness after uncomplicated phacoemulsification.”
Dr. El Habbak also pointed out that intraocular surgery increases retinal vascular permeability, resulting in increased macular edema.
“Bevacizumab inhibits vascular endothelial growth factor, which is a potent permeability factor implicated in cystoid macular edema,” he said.
Ashraf El Habbak MD, PhD
Dr. El Habbak has no relevant financial interest